The National Institutes of Health's Panel on Clinical Practices for Treatment of HIV Infection has recommended that Viread and Videx EC plus a nonnucleoside reverse transciptase inhibitor not be used as in initial regimen for treatment-naive patients because studies show the regimen has a high failure rate. They panel also recommended that Kaletra be dosed once daily for treatment-naive patients. Once-daily Kaletra dosing is not recommended for treatment-experienced patients.
